A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Principal Investigator
Sue Yom, MD PhD
Status
Closed to Accrual
Date Opened To Accrual
October 27 2014
Date Closed to Accrual
February 07 2017
Disease Site
Head and Neck [HN]
Head and Neck
Phase
II
Developmental Therapeutics
No
Primary Objective
To select the arm(s) achieving a 2-year progression-free survival rate of ≥ 85% without unacceptable swallowing toxicity at 1 year
Patient Population
Pathologically (histologically or cytologically) proven diagnosis of squamous cell
carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma) of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls); patients must have positive immunohistochemical staining for p16, as confirmed by the NRG Oncology Biospecimen Bank, prior to randomization.
Target Accrual
296
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.